QBiotics Ltd is not able to provide treatment with EBC-46 at this time. Recruitment for the two Phase I safety studies in Australia and New Zealand is now closed and QBiotics does not currently have any other open trials. QBiotics will proceed to analyse and report on the Phase I studies, and then make a determination on how best to continue with clinical development for eventual approval of EBC-46. Details of any future clinical trials will be posted on the company’s website and international clinical trial registries, such as ClinicalTrials.gov.
Please note that:
- QBiotics is not involved in assessing patients or recommending eligibility – this is something only the independent treating clinicians can determine.
- QBiotics staff are unable to discuss any aspects of these trials with potential patients and unfortunately we cannot respond to emails or phone requests for information about these clinical trials from the general public.